MaxQ Medical Lands $31.5 Million to Bring Ultrasound Prostate Treatment Out of the Lab
A Sunnyvale medtech startup thinks it can crack one of urology's persistent challenges: treating prostate disease without forcing patients to choose between inadequate relief and significant side effects.
MaxQ Medical said August 20 it closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures, with backing from returning investor Hillside Capital. The company is developing what it describes as the first system to combine real-time ultrasound imaging with focused therapeutic ultrasound in a single outpatient procedure. The device threads through the urethra to treat benign prostatic hyperplasia, with ambitions to eventually tackle localized prostate cancer.
According to an SEC filing, the round brought in $20 million in fresh capital alongside $11.5 million converted from earlier SAFE notes. Eleven investors participated. The company declined to share its valuation.
Decades-Old Stanford Research Moves Toward the Clinic
At the heart of MaxQ's platform sits technology that has been percolating at Stanford for years. The system relies on capacitive micromachined ultrasound transducers, semiconductor-based devices pioneered by Pierre Khuri-Yakub, a Stanford professor who co-founded MaxQ's parent company, Orchard Ultrasound Innovation, and now serves as the startup's chief scientific officer.
While CMUTs have been studied extensively, MaxQ appears to be the first to package them into a complete imaging-and-therapy device. The approach allows what the company calls "tissue-selective" ablation, destroying targeted prostate tissue while sparing the surrounding urethra.
MaxQ spun out of Orchard in 2023 as a Delaware corporation. Both entities share an address in Sunnyvale. LinkedIn lists the startup's headcount somewhere between two and ten employees, a skeletal team for a company now flush with Series A capital.
A Crowded Field, Murky Reimbursement
The device remains investigational in the United States. MaxQ has set its sights first on benign prostatic hyperplasia, the age-related prostate enlargement that affects 29–33% of men 65 and older, according to the NIDDK. From there, the plan extends to focal therapy for localized cancer and eventually diagnostic applications including biopsy guidance and tumor mapping.
That pathway will not be simple. Recent American Urological Association guidelines have explicitly cautioned against using high-intensity focused ultrasound to treat BPH-related symptoms outside clinical trials, a reminder of the regulatory and clinical hurdles ahead. A new reimbursement code for transrectal BPH treatment using focused ultrasound takes effect July 1, 2025, suggesting payers are at least watching the research develop.
"Men with prostate disease have had to choose between treatments that don't do enough and treatments that come with consequential tradeoffs and side-effects," CEO Amir Tehrani said in a statement.
MaxQ will face direct competition from Profound Medical, whose TULSA-PRO system uses MRI guidance to deliver transurethral ultrasound ablation and has secured favorable reimbursement codes. Transrectal focused ultrasound devices from companies like EDAP TMS and Sonablate have been marketed for prostate cancer, though adoption for BPH in the U.S. remains limited.
Then there is the broader landscape of minimally invasive BPH treatments, many with established clinical support and growing commercial momentum. PROCEPT BioRobotics' water-jet ablation system, Teleflex's UroLift implants, Boston Scientific's Rezūm steam therapy, and various laser procedures have all carved out market share. PROCEPT, for one, has reported sustained revenue growth in recent quarterly filings.
Corporate Venture Interest Signals Broader Sector Bet
The involvement of Olympus Innovation Ventures, the corporate venture arm of the medical device giant, may prove significant. Launched in 2021, the fund deploys between $500,000 and $10 million across seed through growth-stage companies, with a clinical emphasis that includes urology. Gabriela Kaynor chairs the fund.
"There's a strong need in urology for technology that allows physicians to see and treat the prostate in one setting," Kaynor said.
S3 Ventures, a Texas firm managing over $1 billion, invests in healthcare technology from seed through Series B. Atlantic Blue Ventures, a Florida-registered entity formed in 2023, maintains a lower public profile with limited disclosure around fund size or prior medtech investments.
MaxQ plans to use the proceeds to expand its team and push its clinical program forward. A small equity filing from mid-2024 showed $50,000 raised from 17 investors, with John N. Irwin III signing on as interim CEO. Tehrani now holds the top executive role, while Amir Abolfathi serves as executive chairman.
Whether the company can navigate the clinical, regulatory, and commercial gauntlet ahead remains to be seen. For now, it has the capital to find out.
